Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 2, 2009, Pages 130-138

  Miyaji, Yoshiro ^a   Ishizuka, Tomoko ^a   Kawai, Kenji ^b   Hamabe, Yoshimi ^c   Miyaoka, Teiji ^d   Oh Hara, Toshinari ^e   Ikeda, Toshihiko ^f   Kurihara, Atsushi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Pharmacokinetics Bioanalysis Center   (Japan)

^c Institute of Accelerator Analysis Ltd   (Japan)

^d Institute of Accelerator Analysis Ltd   (Japan)

^e SEKISUI CHEMICAL CO LTD   (Japan)

^f YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

Absolute bioavailability; Accelerator mass spectrometry; Dog; Microdosing; Simultaneous oral and intravenous dosing

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; R 142086; R 142086 C 14; UNCLASSIFIED DRUG; AMIDINE; CARBON; N (4 (1 (ACETIMIDOYL)PIPERIDIN 4 YLOXY) 3 CARBAMOYLPHENYL) N (3 (3 AMIDINOPHENYL) 2 FLUORO 2 PROPENYL)SULFAMOYLACETIC ACID; N-(4-(1-(ACETIMIDOYL)PIPERIDIN-4-YLOXY)-3-CARBAMOYLPHENYL)-N-(3-(3-AMIDINOPHENYL)-2-FLUORO-2-PROPENYL)SULFAMOYLACETIC ACID; SULFONAMIDE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; EVALUATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PLASMA; URINE;

ADMINISTRATION, ORAL; AMIDINES; ANIMALS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; EVALUATION STUDIES AS TOPIC; FEMALE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; PLASMA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFONAMIDES;

EID: 67649306825     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.130     Document Type: Article

References (12)

1. Garner, R. C., Barker, J., Flavell, C., Garner, J. V., Whattam, M., Young, G. C., Cussans, N., Jezequel, S. and Leong, D.: A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J. Pharm. Biomed. Anal., 24: 197-209 (2000).
2. Young, G., Ellis, W., Ayrton, J., Hussey, E. and Adamkiewicz, B.: Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotic., 31: 619-632 (2001).
3. Garner, R. C., Goris, I., Laenen, A. A., Vanhoutte, E., Meuldermans, W., Gregory, S., Garner, J. V., Leong, D., Whattam, M., Calam, A. and Snel, C. A.: Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled(R)-6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl- 2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos., 30: 823-830 (2002).
4. 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol., 45: 1198-1205 (2005).
5. Klem, B., Lappin, G., Nicholson, S., van de Wetering, J., de Vries, D. E., Oosterhuis, B. and Garner, R. C.: Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J. Clin. Pharmacol., 46: 456-460 (2006).
6. Lappin, G., Kuhnz, W., Jochemsen, R., Kneer, J., Chaudhary, A., Oosterhuis, B., Drijfhout,W. J., Rowland, M. and Garner, R. C.: Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol Ther., 80: 203-215 (2006).
7. Strong, J. M., Dutcher, J. S., Lee, W. K. and Atkinson, A. J. Jr.: Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin. Pharmacol. Ther., 18: 613-622 (1975).
8. Hage, K., Buhl, K., Fischer, C. and Knebel, N. G.: Estimation of the absolute bioavailability of flecainide using stable isotope technique. Eur. J. Clin. Pharmacol., 48: 51-55 (1995).
9. Rubin, G. M., Waschek, J. A., Pond, S. M., Effeney, D. J. and Tozer, T. N.: Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J. Pharmacokinet Biopharm., 15: 615-631 (1987).
10. Sandhu, P., Vogel, J. S., Rose, M. J., Ubick, E. A., Brunner, J. E., Wallace, M. A., Adelsberger, J. K., Baker, M. P., Henderson, P. T., Pearson, P. G. and Baillie, T. A.: Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos., 32: 1254-1259 (2004).
11. 14C measurements. Radiocarbon, 35: 295-300 (1993).
12. Lappin, G., Rowland, M. and Garner, R. C.: The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol., 2: 419-427 (2006).